Phase I Study of Bryostatin 1 in Advanced Cancer Patients
Author Information
Author(s): J. Prendiville, D. Crowther, N. Thatcher, P.J. Woll, B.W. Fox, A. McGown, N. Testa, P. Stem, R. McDermott, M. Potter, G.R. Pettit
Primary Institution: Paterson Institute and Christie Hospital NHS Trust, Manchester, UK
Hypothesis
Can bryostatin 1 be safely administered to patients with advanced cancer and what are its biological effects?
Conclusion
Bryostatin 1 can be administered safely at doses of 35 to 50 µg m-2, but no antitumor effects were observed in this study.
Supporting Evidence
- Bryostatin 1 was administered as an intravenous infusion over one hour.
- The maximum tolerated dose was found to be 50 µg m-2.
- Common side effects included myalgia and flu-like symptoms.
- Significant decreases in blood cell counts were observed at the highest dose.
- No antitumor effects were observed in the study.
Takeaway
Doctors tested a new cancer drug called bryostatin 1 on 19 patients to see if it was safe and if it worked, but they found it didn't help fight cancer.
Methodology
Nineteen patients with advanced solid tumors received intravenous bryostatin 1 in escalating doses over a maximum of three treatment cycles.
Limitations
The study was limited by the small sample size and the lack of observed antitumor effects.
Participant Demographics
All participants had advanced solid tumors for which conventional therapy was not available or had failed.
Want to read the original?
Access the complete publication on the publisher's website